natgillin/translations-raw huggingface dataset:
Do not take macrogol (a drug used as laxative) for one hour before and one hour after taking levetiracetam as this may results in a reduction of its effect. 
Ne jemljite makrogola (učinkovina, ki se uporablja kot laksativ) eno uro pred in eno uro po jemanju levetiracetama, ker lahko zmanjša učinek levetiracetama.
Other unidentified components accounted only for 0.6% of the dose. 
Druge, neidentificirane sestavine predstavljajo le 0,6 % odmerka.
Total Daily Dose 
Celokupni dnevni odmerek
If not used immediately, in-use storage time and conditions are the responsibility of the user. 
V primeru, da se ga ne uporabi takoj, je za čas in pogoje shranjevanja odgovoren uporabnik.
• encephalopathy (see sub-section “Tell your doctor immediately” for a detailed description of symptoms); 
• encefalopatija (glejte podpoglavje “Takoj obvestite zdravnika” za podroben opis simptomov)
Available data in children did not suggest impact on growth and puberty. 
Podatki, ki so na razpolago pri otrocih, ne kažejo na vpliv na rast in puberteto.
The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal. 
Zahteve glede predložitve rednega posodobljenega poročila o varnosti cepiva za to cepivo so določene v seznamu referenčnih datumov EU (seznamu EURD), opredeljenem v členu 107c(7) Direktive 2001/83/ES, in vseh kasnejših posodobitvah, objavljenih na evropskem spletnem portalu o zdravilih.
Dose adjustment is not required. 
Prilagoditev odmerjanja ni potrebna.
The mechanism of this risk is not known. 
Mehanizem tveganja še ni znan.
No impact on fertility was detected in animal studies (see section 5.3). 
V študijah na živalih vpliva na plodnost niso odkrili (glejte poglavje 5.3).
* Prevalence is significantly higher in Japanese patients when compared to non-Japanese patients. 
* Prevalenca je bistveno večja pri japonskih bolnikih v primerjavi z ne-japonskimi bolniki.
Physiological changes during pregnancy may affect levetiracetam concentration. 
Fiziološke spremembe med nosečnostjo lahko vplivajo na koncentracijo levetiracetama.
Cases of encephalopathy generally occurred at the beginning of the treatment (few days to a few months) and were reversible after treatment discontinuation. 
Primeri encefalopatije so se običajno pojavili na začetku zdravljenja (od nekaj dni do nekaj mesecev) in so bili reverzibilni, ko se je zdravljenje prekinilo.
Dose in adults and adolescents (from 16 years of age): 
Odmerjanje pri odraslih in mladostnikih (od 16. leta starosti):
He/she may decide if your dose should be adjusted. 
Odločil se bo, ali je vaš odmerek potrebno prilagoditi.
This decrease is more pronounced during the third trimester (up to 60% of baseline concentration before pregnancy). 
To zmanjšanje koncentracije je bolj izrazito v tretjem trimesečju (do 60 % glede na običajno koncentracijo pred nosečnostjo).
Then CLcr is adjusted for body surface area (BSA) as follows: 
CLcr je prilagojen na telesno površino (BSA, body surface area) na naslednji način:
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines, including medicines obtained without a prescription. 
Obvestite zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo, tudi če ste ga dobili brez recepta.
Hydrolysis of the acetamide group was measurable in a large number of tissues including blood cells. 
Hidrolizo acetamidne skupine so izmerili v številnih tkivih vključno s krvnimi celicami.
The pharmacokinetic and safety profiles did not identify any safety concerns. 
Farmakokinetični in varnostni profil nista pokazala nobenih vplivov na varnost.
Levetiracetam Hospira must be administered twice a day, once in the morning and once in the evening, at about the same time each day. 
Zdravilo Levetiracetam Hospira morate prejeti dvakrat na dan, enkrat zjutraj in enkrat zvečer, vsak dan ob približno istem času.
EXP Use immediately after dilution. 
EXP: Uporabite takoj po redčenju.
• limp or difficulty walking. 
• šepanje ali težave pri hoji.
Tell your doctor immediately, or go to your nearest emergency department, if you experience: 
Nemudoma obvestite zdravnika ali obiščite oddelek za nujno medicinsko pomoč, če opazite:
This leaflet was last revised in month/YYYY. 
Navodilo je bilo nazadnje revidirano dne {mesec LLLL}.
Chemical and physical in-use stability of the diluted product stored in PVC bags has been demonstrated for 24 hours at 30 °C and at 2-8 °C. 
Kemična in fizikalna stabilnost razredčenega zdravila med uporabo, shranjenega v PVC vrečkah, sta bili dokazani za obdobje 24 ur pri temperaturi 30 °C in pri od 2 do 8 °C.
Appropriate clinical management of pregnant women treated with levetiracetam should be ensured. 
Zagotoviti je treba ustrezno klinično spremljanje nosečnic, ki se zdravijo z levetiracetamom.
However, long term effects on learning, intelligence, growth, endocrine function, puberty and childbearing potential in children remain unknown. 
Vendar pa dolgoročni učinki na učenje, inteligenco, rast, delovanje žlez, puberteto in rodnost pri otrocih ostajajo neznani.
• Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached. 
• ob vsakršni spremembi sistema za obvladovanje tveganj, zlasti kadar je tovrstna sprememba posledica prejema novih informacij, ki lahko privedejo do znatne spremembe razmerja med koristmi in tveganji,ali kadar je ta sprememba posledica tega, da je bil dosežen pomemben mejnik (farmakovigilančni ali povezan z zmanjševanjem tveganja).
ks= 0.55 in Children to less than 13 years and in adolescent female; ks= 0.7 in adolescent male 
ks = 0,55 pri otrocih, mlajših od 13 let in pri mladostnicah; ks = 0,7 pri mladostnikih moškega spola
• elevated/abnormal values in a liver function test; 
• povišane/nenormalne vrednosti testov jetrnih funkcij;
Prevalence is significantly higher in Japanese patients when compared to non-Japanese patients; 
Pogostnost je bistveno večja pri japonskih bolnikih v primerjavi z ne-japonskimi bolniki;
The major route of excretion was via urine, accounting for a mean 95% of the dose (approximately 93% of the dose was excreted within 48 hours). 
Glavna pot izločanja je z urinom, s katerim se izloči povprečno 95 % odmerka (približno 93 % odmerka se izloči v 48 urah).
This recommendation is based on a study in adult renally impaired patients. 
To priporočilo temelji na študiji pri odraslih bolnikih z ledvično okvaro.
Adverse reactions are presented in the order of decreasing seriousness and their frequency is defined as follows: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000) and very rare (<1/10,000). 
Neželeni učinki so navedeni po padajoči resnosti in njihova pogostnost je opredeljena takole: zelo pogosti (≥1/10); pogosti (≥1/100 do <1/10); občasni (≥1/1.000 do <1/100); redki (≥1/10.000 do <1/1.000); zelo redki (<1/10.000).
Read all of this leaflet carefully before you or your child start using this medicine because it contains important information for you. 
Pred začetkom uporabe zdravila vi ali vaš otrok natančno preberite navodilo, ker vsebuje za vaju pomembne podatke!
The patients had to present with unprovoked partial seizures or with generalized tonic-clonic seizures only. 
Bolniki so morali imeti neizzvane parcialne napade ali samo generalizirane tonično-klonične napade.
Your total daily dose and frequency of administration remain identical. 
Vaš celokupni dnevni odmerek in pogostost uporabe ostaneta enaki.
There is no modification of the clearance after repeated administration. 
Očistek se po ponavljajočem dajanju ne spremeni.
One was obtained by hydroxylation of the pyrrolidone ring (1.6 % of the dose) and the other one by opening of the pyrrolidone ring (0.9% of the dose). 
Eden nastane s hidroksilacijo pirolidonskega obroča (1,6 % odmerka), drugi z odprtjem pirolidonskega obroča (0,9 % odmerka).
Oral contraceptives and other pharmacokinetics interactions 
Peroralni kontraceptivi in druge farmakokinetične interakcije
Therefore, caution is recommended in those patients when performing skilled tasks, e.g. driving vehicles or operating machinery. 
Ti bolniki morajo biti zato previdni pri izvajanju zahtevnih opravil, npr. pri vožnji vozil ali upravljanju strojev.
Patients are advised not to drive or use machines until it is established that their ability to perform such activities is not affected. 
Bolnikom svetujemo, naj ne vozijo ali upravljajo s stroji, dokler ni potrjeno, da ni vpliva na njihovo sposobnost izvajanja teh dejavnosti.
Levetiracetam caused mild induction of CYP2B6 and CYP3A4. 
Levetiracetam je povzročil blago indukcijo CYP2B6 in CYP3A4.
There was no effect on embryomortality and no increased incidence of malformations. 
Umrljivosti zarodka in povečanje pojava malformacij ni bilo.
The apparent body weight adjusted clearance was approximately 30% higher than in epileptic adults. 
Navidezni telesni očistek je bil približno 30 % večji kot pri odraslih z epilepsijo.
The volume of distribution of levetiracetam is approximately 0.5 to 0.7 l/kg, a value close to the total body water volume. 
Volumen porazdelitve levetiracetama je približno 0,5 do 0,7 l/kg, kar je blizu vrednosti celotnega volumna vode v telesu.
• a more severe form of rash causing skin peeling in more than 30% of the body surface (toxic epidermal necrolysis) 
• hujšo obliko izpuščaja, ki povzroči luščenje kože na več kot 30 % telesne površine (toksična epidermalna nekroliza)
Pharmacotherapeutic group: antiepileptics, other antiepileptics, ATC code: N03AX14. 
Farmakoterapevtska skupina: antiepileptiki, drugi antiepileptiki, oznaka ATC: N03AX14.
Complete blood cell counts are advised in patients experiencing important weakness, pyrexia, recurrent infections or coagulation disorders (section 4.8). 
Priporoča se določitev celotne krvne slike pri bolnikih, ki imajo močno slabost, pireksijo, ponavljajoče okužbe ali motnje v koagulaciji (poglavje 4.8)
Levetiracetam has minor or moderate influence on the ability to drive and use machines. 
Levetiracetam ima blag ali zmeren vpliv na sposobnost vožnje in upravljanja s stroji.
However, if levetiracetam treatment is needed during breastfeeding, the benefit/risk of the treatment should be weighed considering the importance of breastfeeding. 
Če je zdravljenje z levetiracetamom v obdobju dojenja potrebno, se mora pretehtati razmerje med koristjo in tveganjem zdravljenja glede na pomembnost dojenja.
Patients (and caregivers of patients) should be advised to seek medical advice should signs of depression and/or suicidal ideation or behaviour emerge. 
Bolnikom (in skrbnikom bolnikov) je treba svetovati, naj poiščejo zdravniško pomoč, če se pojavijo znaki depresije in/ali samomorilnega razmišljanja in vedenja.
• decreased number of all blood cell types; 
• zmanjšano število vseh vrst krvnih celic;
The metabolite ucb L057 is pharmacologically inactive. 
Presnovek ucb L057 ni farmakološko aktiven.
When you first start taking Levetiracetam Hospira, your doctor will prescribe you a lower dose for 2 weeks before giving you the lowest general dose. 
Na začetku jemanja zdravila Levetiracetam Hospira vam bo zdravnik, preden vam bo predpisal najnižji običajni odmerek, za dva tedna predpisal nižji odmerek.
The use of levetiracetam has been very rarely associated with acute kidney injury with a time to onset ranging from a few days to several months. 
Uporaba levetiracetama je bila zelo redko povezana z akutno poškodbo ledvic, ki se lahko pojavi v razponu od nekaj dni do nekaj mesecev od uporabe.
You should not drive or use machines until it is established that your ability to perform such activities is not affected. 
Ne smete voziti ali upravljati strojev, dokler ni potrjeno, da zdravilo ne vpliva na vašo sposobnost izvajanja teh dejavnosti.
• severe allergic reactions (DRESS, anaphylactic reaction [severe and important allergic reaction], Quincke's oedema [swelling of the face, lips, tongue and throat]); 
• hude alergijske reakcije (DRESS, anafilaktična reakcija [huda in pomembna alergijska reakcija], Quinckejev edem [otekanje obraza, ustnic, jezika in žrela]);
nasopharyngitis (infection of the nose or throat); somnolence (sleepiness), headache. 
nazofaringitis (okužba nosu ali žrela); somnolenca (zaspanost), glavobol.
Therefore patients should be monitored for signs of depression and/or suicidal ideation and behaviours and appropriate treatment should be considered. 
Zato je treba bolnike med zdravljenjem nadzirati glede znakov depresije in/ali samomorilnega razmišljanja in vedenja ter razmisliti o ustreznem zdravljenju.
Infusion Time Frequency of administration 
Čas infuzije Pogostost uporabe
Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu 
Podrobne informacije o tem zdravilu so objavljene na spletni strani Evropske agencije za zdravila http://www.ema.europa.eu
Conversion to or from oral to intravenous administration can be done directly without titration. 
Prehod na ali od peroralne k intravenski uporabi je lahko neposreden brez titracije.
What Levetiracetam Hospira is and what it is used for What you need to know before you are given Levetiracetam Hospira How Levetiracetam Hospira is given Possible side effects 
Kaj je zdravilo Levetiracetam Hospira in za kaj ga uporabljamo Kaj morate vedeti, preden boste prejeli zdravilo Levetiracetam Hospira Kako se daje zdravilo Levetiracetam Hospira Možni neželeni učinki
However subjects, who took levetiracetam in the long-term open label follow-up study, did not experience a worsening, on average, in their behavioural and emotional functioning; in particular measures of aggressive behaviour were not worse than baseline. 
Kljub temu pa se osebam, ki so jemale levetiracetam med dolgotrajno, odprto, sledilno študijo, v povprečju niso poslabšale njihove vedenjske in emocionalne funkcije; natančneje, rezultati meritev agresivnega obnašanja niso bili slabši od začetnih vrednosti.
• signs of serious mental changes or if someone around you notices signs of confusion, somnolence (sleepiness), amnesia (loss of memory), memory impairment (forgetfulness), abnormal behaviour or other neurological signs including involuntary or uncontrolled movements. 
• znaki resnih duševnih sprememb ali če kdo okoli vas opazi znake zmedenosti, somnolence (zaspanost), amnezije (izguba spomina), oslabljen spomin (pozabljivost), neobičajno vedenje ali druge nevrološke znake, vključno z nehotenim ali nenadzorovanim gibanjem.
A large amount of post-marketing data on pregnant women exposed to levetiracetam monotherapy (more than 1800, among which in more than 1500 exposure occurred during the 1st trimester) do not suggest an increase in the risk for major congenital malformations. 
Veliko podatkov, pridobljenih v obdobju trženja, o nosečnicah, ki so bile izpostavljene samostojnemu zdravljenju z levetiracetamom (več kot 1800, od katerih jih je bilo več kot 1500 izpostavljenih med prvim trimesečjem), ne kažejo na povečanje tveganja za večje prirojene malformacije.
In human hepatocytes in culture, levetiracetam had little or no effect on CYP1A2, SULT1E1 or UGT1A1. 
V kulturi človeških hepatocitov je imel levetiracetam majhen učinek ali pa ni imel učinka na CYP1A2, SULT1E1 ali UGT1A1.
At the beginning of the treatment or at dose increase side effects like sleepiness, tiredness and dizziness may be more common. 
Na začetku zdravljenja ali po povečanju odmerka lahko neželeni učinki, kot so na primer zaspanost, utrujenost in omotica, postanejo pogostejši.
Nevertheless, the concentration of this metabolite remains low. 
Kljub temu ostane koncentracija primarnega presnovka nizka.
This medicinal product is for single use only, any unused solution should be discarded. 
Zdravilo je samo za enkratno uporabo, neuporabljeno raztopino je treba zavreči.
A doctor or a nurse will administer you Levetiracetam Hospira as an intravenous infusion. 
Zdravnik ali medicinska sestra vam bo zdravilo Levetiracetam Hospira dal kot intravensko infuzijo.
Hypersensitivity to the active substance or other pyrrolidone derivatives or to any of the excipients listed in section 6.1. 
Preobčutljivost na učinkovino ali druge pirolidonske derivate ali katero koli pomožno snov, navedeno v poglavju 6.1.
The plasma half-life in adults was 7±1 hours and did not vary either with dose, route of administration or repeated administration. 
Plazemski razpolovni čas pri odraslih je 7  1 ur in se ne spreminja z odmerkom, potjo uporabe ali ponavljajočo se uporabo.
• swelling of the face, lips, tongue and throat (Quincke's oedema) 
• otekanje obraza, ustnic, jezika in žrela (Quinckejev edem)
If you notice any slow down in the growth or unexpected puberty development of your child, please contact your doctor. 
če ste pri otroku opazili počasnejšo rast ali nepričakovan razvoj v puberteti, se posvetujte z zdravnikom.
The physician should prescribe the most appropriate pharmaceutical form, presentation and strength according to age, weight and dose. 
Zdravnik mora glede na starost, telesno maso in odmerek predpisati najustreznejšo farmacevtsko obliko, velikost pakiranja in jakost.
• decreased number of blood platelets, decreased number of white blood cells; 
zmanjšano število krvnih ploščic, zmanjšano število belih krvnih celic;
The dialyser extraction efficiency is 60% for levetiracetam and 74% for the primary metabolite. 
Učinkovitost dializne ekstrakcije levetiracetama je 60 %, primarnega presnovka pa 74 %.
CLcr (ml/min/1.73 m 2) = ---------------------------- x 1.73 BSA subject (m 
CLcr (ml/min/1,73 m 2) = ----------------------- x 1,73 BSA bolnika (m
Following dialysis, a 250 to 500 mg supplemental dose is recommended. 
Po dializi je priporočljiv dodatni odmerek od 250 do 500 mg.
Withdrawal Volume Volume of Diluent 
Odmerek Odvzeti volumen Volumen redčila
Results related to behavioural and emotional functioning indicated a worsening in levetiracetam treated patients on aggressive behaviour as measured in a standardised and systematic way using a validated instrument (CBCL - Achenbach Child Behaviour Checklist). 
Rezultati povezani z vedenjskimi in emocionalnimi funkcijami kažejo pri bolnikih, ki se zdravijo z levetiracetamom, poslabšanje agresivnega obnašanja, ki se izmeri na standardiziran in sistematičen način z uporabo validiranega merskega instrumenta (CBCL - Achenbach Child Behavior Checklist).
Levetiracetam Hospira may impair your ability to drive or operate any tools or machinery, as it may make you feel sleepy. 
Zdravilo Levetiracetam Hospira lahko oslabi vašo sposobnost vožnje ali upravljanja z orodjem ali stroji, saj lahko zdravilo Levetiracetam Hospira povzroči zaspanost.
In addition, it partially reverses the reductions in GABA- and glycine-gated currents induced by zinc and β-carbolines. 
Poleg tega delno preprečuje inhibicijo GABA in glicinskih kanalov povzročeno z Zn in β- karbolini.
Furthermore, levetiracetam has been shown in in vitro studies to bind to a specific site in rodent brain tissue. 
Nadalje se je za levetiracetam v in vitro študijah pokazalo, da se veže na specifično mesto v možganskem tkivu glodalcev.
Adverse reactions reported in clinical studies (adults, adolescents, children and infants > 1 month) and from post-marketing experience are listed in the following table per System Organ Class and per frequency. 
Neželeni učinki, o katerih so poročali v kliničnih študijah (odrasli, mladostniki, otroci in dojenčki, starejši od 1 meseca) in v postmarketinškem obdobju, so navedeni v spodnji preglednici po organskih sistemih in pogostnosti.
Due to possible different individual sensitivity, some patients might experience somnolence or other central nervous system related symptoms, especially at the beginning of treatment or following a dose increase. 
Pri nekaterih bolnikih se lahko zaradi različne individualne občutljivosti predvsem na začetku zdravljenja ali po povečanju odmerka pojavi somnolenca ali drugi simptomi, povezani s centralnim živčnim sistemom.
Box of 10 or 25 vials 
Škatla z 10 ali 25 vialami
Pre-marketing data from clinical studies conducted in adults indicate that levetiracetam did not influence the serum concentrations of existing antiepileptic medicinal products (phenytoin, carbamazepine, valproic acid, phenobarbital, lamotrigine, gabapentin and primidone) and that these antiepileptic medicinal products did not influence the pharmacokinetics of levetiracetam. 
Predmarketinški podatki iz kliničnih študij, izvedenih pri odraslih kažejo, da levetiracetam ne vpliva na serumsko koncentracijo drugih antiepileptičnih zdravil (fenitoina, karbamazepina, valprojske kisline, fenobarbitala, lamotrigina, gabapentina in primidona), in da ta antiepileptična zdravila ne vplivajo na farmakokinetiko levetiracetama.
Six-month seizure freedom was achieved in 73.0% of levetiracetam-treated patients and 72.8% of carbamazepine-CR treated patients; the adjusted absolute difference between treatments was 0.2% (95% CI:-7.8 8.2). 
73,0 % bolnikov, ki so se zdravili z levetiracetamom, in 72,8 % bolnikov, ki so se zdravili s karbamazepinom z nadzorovanim sproščanjem (CR) je bilo šest mesecev brez napadov; prilagojena absolutna razlika med zdravljenjema je bila 0,2 % (95-% CI: 7,8-8,2).
Пфайзер Люксембург САРЛ, Клон България Тел. 
Пфайзер Люксембург САРЛ, Клон БългарияHospira UK Limited Тел.
This binding site is the synaptic vesicle protein 2A, believed to be involved in vesicle fusion and neurotransmitter exocytosis. 
To vezavno mesto je sinaptični vezikularni protein 2A, ki naj bi bil udeležen pri fuziji veziklov in eksocitozi nevrotransmiterjev.
Directions for the proper use of Levetiracetam Hospira is provided in section 3. 
Navodila za pravilno uporabo zdravila Levetiracetam Hospira se nahajajo v poglavju 3.
Should your doctor decide to stop your Levetiracetam Hospira treatment, he/she will instruct you about the gradual withdrawal of Levetiracetam Hospira. 
Če se bo vaš zdravnik odločil za prekinitev zdravljenja z zdravilom Levetiracetam Hospira, vam bo dal napotke o postopni ukinitvi zdravila Levetiracetam Hospira.
In vitro, levetiracetam and its primary metabolite have been shown not to inhibit the major human liver cytochrome P450 isoforms (CYP3A4, 2A6, 2C9, 2C19, 2D6, 2E1 and 1A2), glucuronyl transferase (UGT1A1 and UGT1A6) and epoxide hydroxylase activities. 
In vitro so pokazali, da levetiracetam in njegov primarni presnovek ne zavirata aktivnosti glavnih izooblik človeškega jetrnega citokroma P450 (CYP3A4, 2A6, 2C9, 2C19, 2D6, 2E1 in 1A2), glukuronil-transferaze (UGT1A1 in UGT1A6) in epoksid-hidroksilaze.
General dose: between 1,000 mg and 3,000 mg each day. 
Običajni odmerek: med 1.000 mg in 3.000 mg na dan.
If you stop using Levetiracetam Hospira: 
Če ste prenehali uporabljati zdravilo Levetiracetam Hospira:
Since there was limited exposure for levetiracetam intravenous use and since oral and intravenous formulations are bioequivalent, the safety information of levetiracetam intravenous will rely on levetiracetam oral use. 
Zaradi omejene izpostavljenosti intravenski uporabi levetiracetama in zaradi bioekvivalence med peroralno in intravensko obliko informacije o varnosti intravenske uporabe levetiracetama temeljijo na peroralni uporabi levetiracetama.
A small number of people being treated with antiepileptics such as Levetiracetam Hospira have had thoughts of harming or killing themselves. 
pri majhnem številu bolnikov, ki so se zdravili z antiepileptiki, kot je zdravilo Levetiracetam Hospira, so se pojavile misli na samopoškodovanje ali samomor.
• sudden decrease in kidney function; 
• nenadno zmanjšanje delovanja ledvic;
• uncontrollable muscle spasms affecting the head, torso and limbs, difficulty in controlling movements, hyperkinesia (hyperactivity); 
• nekontrolirani mišični spazmi, ki prizadenejo glavo, trup in okončine, težave pri nadzoru gibanja, hiperkinezija (hiperaktivnost);